MINERVA NEUROSCIENCES INC (NERV) Stock Price, Quote, News and Overview
NASDAQ:NERV - Nasdaq - US6033802058 - Common Stock - Currency: USD
NERV Quote, Performance and Key Statistics
NASDAQ:NERV (2/21/2025, 8:00:01 PM)
1.82
-0.02 (-1.09%)
The current stock price of NERV is 1.82 USD. In the past month the price decreased by -15.74%. In the past year, price decreased by -73.51%.
NERV Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About NERV
Company Profile
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2014-06-25. The company is engaged in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and have exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson's disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of the major depressive disorder (MDD). Roluperidone is a compound that blocks serotonin, sigma, and a-adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson's disease and for other neurodegenerative disorders.
Company Info
MINERVA NEUROSCIENCES INC
1601 Trapelo Road, Suite 284
Waltham MASSACHUSETTS 02451 US
CEO: Remy Luthringer
Employees: 9
Company Website: https://www.minervaneurosciences.com/
Investor Relations: http://ir.minervaneurosciences.com/
Phone: 16176007373
MINERVA NEUROSCIENCES INC / NERV FAQ
What is the stock price of MINERVA NEUROSCIENCES INC today?
The current stock price of NERV is 1.82 USD. The price decreased by -1.09% in the last trading session.
What is the ticker symbol for MINERVA NEUROSCIENCES INC stock?
The exchange symbol of MINERVA NEUROSCIENCES INC is NERV and it is listed on the Nasdaq exchange.
On which exchange is NERV stock listed?
NERV stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MINERVA NEUROSCIENCES INC stock?
6 analysts have analysed NERV and the average price target is 5.1 USD. This implies a price increase of 180.22% is expected in the next year compared to the current price of 1.82. Check the MINERVA NEUROSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MINERVA NEUROSCIENCES INC worth?
MINERVA NEUROSCIENCES INC (NERV) has a market capitalization of 12.72M USD. This makes NERV a Nano Cap stock.
How many employees does MINERVA NEUROSCIENCES INC have?
MINERVA NEUROSCIENCES INC (NERV) currently has 9 employees.
What are the support and resistance levels for MINERVA NEUROSCIENCES INC (NERV) stock?
MINERVA NEUROSCIENCES INC (NERV) has a resistance level at 1.97. Check the full technical report for a detailed analysis of NERV support and resistance levels.
Should I buy MINERVA NEUROSCIENCES INC (NERV) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NERV, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NERV, evaluating the profitability, health, valuation and growth aspects
- MINERVA NEUROSCIENCES INC (NERV) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MINERVA NEUROSCIENCES INC (NERV) Sales and EPS estimates to see what analysts future expectations are.
- MINERVA NEUROSCIENCES INC (NERV) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MINERVA NEUROSCIENCES INC (NERV) Insider and Institutional Ownership to learn about the owners and their transactions.
- MINERVA NEUROSCIENCES INC (NERV) Stock Chart to make your own analysis
- MINERVA NEUROSCIENCES INC (NERV) Latest news and press-releases to stay up to date.
Does MINERVA NEUROSCIENCES INC (NERV) stock pay dividends?
NERV does not pay a dividend.
When does MINERVA NEUROSCIENCES INC (NERV) report earnings?
MINERVA NEUROSCIENCES INC (NERV) will report earnings on 2025-03-18, after the market close.
What is the Price/Earnings (PE) ratio of MINERVA NEUROSCIENCES INC (NERV)?
MINERVA NEUROSCIENCES INC (NERV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.15).
What is the Short Interest ratio of MINERVA NEUROSCIENCES INC (NERV) stock?
The outstanding short interest for MINERVA NEUROSCIENCES INC (NERV) is 0.38% of its float. Check the ownership tab for more information on the NERV short interest.
NERV Technical Analysis
NERV Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NERV. NERV has a bad profitability rating. Also its financial health evaluation is rather negative.
NERV Financial Highlights
Over the last trailing twelve months NERV reported a non-GAAP Earnings per Share(EPS) of -4.15. The EPS increased by 12.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.74% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NERV Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to NERV. The Buy consensus is the average rating of analysts ratings from 6 analysts.